Development of a Quantitative FMRP Assay for Mouse Tissue Applications
Tatyana Adayev1, Giuseppe LaFauci1, Weimin Xu1
1New York State Institute for Basic Research in Developmental Disabilities, New York, NY 10314, USA.
Abstract:
Fragile X syndrome results from the absence of the FMR1 gene product-Fragile X Mental Retardation Protein (FMRP). Fragile X animal research has lacked a reliable method to quantify FMRP. We report the development of an array of FMRP-specific monoclonal antibodies and their application for quantitative assessment of FMRP (qFMRPm) in mouse tissue. To characterize the assay, we determined the normal variability of FMRP expression in four brain structures of six different mouse strains at seven weeks of age. There was a hierarchy of FMRP expression: neocortex > hippocampus > cerebellum > brainstem. The expression of FMRP was highest and least variable in the neocortex, whereas it was most variable in the hippocampus. Male C57Bl/6J and FVB mice were selected to determine FMRP developmental differences in the brain at 3, 7, 10, and 14 weeks of age. We examined the four structures and found a developmental decline in FMRP expression with age, except for the brainstem where it remained stable. qFMRPm assay of blood had highest values in 3 week old animals and dropped by 2.5-fold with age. Sex differences were not significant. The results establish qFMRPm as a valuable tool due to its ease of methodology, cost effectiveness, and accuracy.
Insights
Researchers developed a new method to quantify Fragile X Mental Retardation Protein (FMRP) in mice. This quantitative FMRP (qFMRPm) assay is accurate, cost-effective, and easy to use for Fragile X research.
Area of Science:
- Neuroscience
- Genetics
- Biochemistry
Background:
- Fragile X syndrome is caused by the lack of Fragile X Mental Retardation Protein (FMRP).
- Existing methods for quantifying FMRP in animal models are unreliable.
- A robust assay is needed to advance Fragile X research.
Purpose of the Study:
- To develop and validate a quantitative method for assessing FMRP levels in mouse tissues.
- To establish baseline FMRP expression levels across different brain regions and mouse strains.
- To investigate developmental changes in FMRP expression.
Main Methods:
- Development of FMRP-specific monoclonal antibodies for quantitative assessment (qFMRPm).
- Analysis of FMRP expression in four brain structures (neocortex, hippocampus, cerebellum, brainstem) across six mouse strains at 7 weeks of age.
- Assessment of FMRP developmental changes in male mice at 3, 7, 10, and 14 weeks of age, including blood samples.
Main Results:
- Established a hierarchy of FMRP expression in the brain: neocortex > hippocampus > cerebellum > brainstem.
- Identified the neocortex as having the highest and least variable FMRP expression.
- Observed a general decline in FMRP expression with age in brain tissues, except for the brainstem, and a significant drop in blood FMRP levels after 3 weeks of age.
Conclusions:
- The quantitative FMRP (qFMRPm) assay is a reliable, cost-effective, and accurate tool for measuring FMRP.
- The assay provides valuable insights into FMRP expression patterns in mouse models of Fragile X syndrome.
- Understanding FMRP variability and developmental changes is crucial for Fragile X research.
